HYPD HYPERION DEFI, INC.

Nasdaq Pharmaceutical Preparations DE CIK: 0001682639
AI RATING
STRONG_SELL
85% Confidence

Investment Thesis

Company faces imminent liquidity crisis with only ~5 months of cash runway ($6.4M cash vs. $14.8M annual operating burn). Despite 1318.8% revenue growth, the cost structure is fundamentally broken: $56.7M+ operating expenses generating just $813.5K revenue is unsustainable. Without immediate capital infusion or dramatic restructuring, insolvency risk is high.

Strengths

  • + Strong gross margin of 62.7% indicates potential unit economics and profitability at scale
  • + Exceptional revenue growth rate of 1318.8% YoY suggests emerging product market traction
  • + Conservative leverage with 0.18x debt/equity ratio limits financial obligations

Risks

  • ! Critical solvency risk: approximately 5 months of cash runway at current burn rate
  • ! Completely unsustainable operating expense structure ($56.7M operating costs on $813.5K revenue)
  • ! Negative operating cash flow of $14.8M with no clear path to profitability without major catalyst
  • ! Company requires immediate external financing or faces near-term bankruptcy

Key Metrics to Watch

Financial Metrics

Revenue
813.5K
Net Income
-45.3M
EPS (Diluted)
$-9.40
Free Cash Flow
-14.8M
Total Assets
51.8M
Cash
6.4M

Profitability Ratios

Gross Margin 62.7%
Operating Margin -5,743.5%
Net Margin -5,570.6%
ROE -110.4%
ROA -87.5%
FCF Margin -1,818.6%

Balance Sheet & Liquidity

Current Ratio
2.68x
Quick Ratio
1.58x
Debt/Equity
0.18x
Debt/Assets
20.7%
Interest Coverage
-122.95x
Long-term Debt
7.5M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-11T12:54:23.377835 | Data as of: 2025-12-31 | Powered by Claude AI